Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 169
  • 695
  • 449
  • 14
  • 31
  • 1
  • 4
  • 647

Found 697 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Towards predicting the analgesic response to ibuprofen following third-molar extraction
18 years - 64 years
All genders
NSAIDs like ibuprofen are pain relievers that are commonly used to reduce pain after dental procedures.  Patients who have their impacted third molar teeth taken out usually experience pain one to three hours after surgery and require pain relievers for at least 2 days. Most people (about 70-90%) experience good …
99 years or below
All genders
Phase 2
There has only been a modest increase in the number of lung transplants each year, increasing from a yearly average of 2,400 between 2009 and 2011, to 2,800 in 2016. Despite this, more than 300 patients died or became too sick to transplant on the lung transplant waiting list in …
55 years - 89 years
All genders
Phase 2
This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways. AMX0035 is not approved …
99 years or below
All genders
Phase 3
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
99 years or below
All genders
Phase 2
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
99 years or below
All genders
Phase 2
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
99 years or below
All genders
Phase 3
This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with bypassing agents, as determined by the frequency of bleeding episodes in enrolled adult subjects who are who have hemophilia A or B with an inhibitor who are not on prophylaxis.
99 years or below
All genders
Phase 2
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
99 years or below
All genders
Phase 1
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
99 years or below
All genders
Phase 2
This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant …
291 - 300 of 697